Euclidean Capital LLC
- SEC CIK
- 0001825034
- Latest filing
- Aug 14, 2026
The latest 13F from Euclidean Capital LLC covers Q2 2026 (filed Aug 14, 2026): 11 long positions worth $439.8M. The top 10 holdings make up 100.0% of the portfolio, and the largest is Vanguard Ftse All-World Ex-US Index Fund at 61.8%. Livermore has 24 filings on Form 13F from this institution, going back to Q1 2021.
What changed in Q2 2026
Share counts compared with Q1 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.
- New
- 1
- Est. +$9.04M
- Added
- 0
- Reduced
- 0
- Sold out
- 0
Top 5 holdings
Share of this quarter's portfolio value
Biggest sells
Reduced and sold-out positions, by estimated amount sold
None this quarter.
Largest weight decreases
Reduced and sold-out positions, by percentage points of the portfolio lost
None this quarter.
Metrics
13F metrics for Q2 2026, computed only from the numbers in the filings. Definitions below.
- Portfolio value
- $439.8M
- +$47.5M (+12.1%) vs. prior quarter
- Positions
- 11
- +1 vs. prior quarter
- Top 10 concentration
- 100.0%
- Top 10 as share of value
- Turnover
- 0.0%
- Q2 2026, one quarter
- Average holding period
- 7.7 quarters
- Weighted by value
How these are calculated
- Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
- Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
- Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
- Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.
13F filings by quarter
22 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.
Peak $906.8M (Q3 2024)
| Quarter | Filed | Positions | Value | Top 3 holdings | Changes | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | 11 | $439.8M | Vanguard Ftse All-World Ex-US Index FundVanguard Morningstar Value ETFiShares MSCI India ETF | vs. Q1 2026 | SEC |
| Q1 2026 | May 15, 2026 | 10 | $392.3M | Vanguard Ftse All-World Ex-US Index FundVanguard Morningstar Value ETFiShares MSCI India ETF | vs. Q4 2025 | SEC |
| Q4 2025 | Feb 17, 2026 | 12 | $369.5M | Vanguard Ftse All-World Ex-US Index FundVanguard Morningstar Value ETFiShares MSCI India ETF | vs. Q3 2025 | SEC |
| Q3 2025 | Nov 14, 2025 | 11 | $238.0M | Vanguard Ftse All-World Ex-US Index FundiShares MSCI India ETFORIC | vs. Q2 2025 | SEC |
| Q2 2025 | Aug 14, 2025 | 11 | $305.7M | Vanguard Ftse All-World Ex-US Index FundiShares MSCI India ETFORIC | vs. Q1 2025 | SEC |
| Q1 2025 | May 15, 2025 | 11 | $266.1M | iShares MSCI India ETFVanguard Ftse All-World Ex-US Index FundFHTX | vs. Q4 2024 | SEC |
| Q4 2024 | Feb 14, 2025 | 11 | $736.7M | SPYiShares MSCI India ETFVanguard Ftse All-World Ex-US Index Fund | vs. Q3 2024 | SEC |
| Q3 2024 | Nov 14, 2024 | 12 | $906.8M | SPYiShares MSCI India ETFVanguard Ftse All-World Ex-US Index Fund | vs. Q2 2024 | SEC |
| Q2 2024 | Aug 14, 2024 | 11 | $795.8M | SPYiShares MSCI India ETFFHTX | vs. Q1 2024 | SEC |
| Q1 2024 | May 15, 2024 | 13 | $780.0M | SPYiShares MSCI India ETFGLD | vs. Q4 2023 | SEC |
| Q4 2023 | Feb 14, 2024 | 13 | $888.5M | SPYGLDiShares MSCI India ETF | vs. Q3 2023 | SEC |
| Q3 2023 | Dec 1, 2023Amended | 13 | $458.4M | GLDiShares MSCI India ETFSPY | vs. Q2 2023 | SEC |
| Q2 2023 | Aug 14, 2023 | 12 | $389.1M | SPYiShares MSCI India ETFGLD | vs. Q1 2023 | SEC |
| Q1 2023 | May 15, 2023 | 10 | $114.0M | iShares MSCI India ETFMEHCQPMVP | vs. Q4 2022 | SEC |
| Q4 2022 | Feb 14, 2023 | 11 | $106.9M | iShares MSCI India ETFMEHCQPMVP | vs. Q3 2022 | SEC |
| Q3 2022 | Nov 14, 2022 | 10 | $107.7M | MEHCQPMVPFHTX | vs. Q2 2022 | SEC |
| Q2 2022 | Aug 15, 2022 | 10 | $117.6M | PMVPMEHCQFHTX | vs. Q1 2022 | SEC |
| Q1 2022 | May 16, 2022 | 11 | $172.1M | PMVPMEHCQFHTX | vs. Q4 2021 | SEC |
| Q4 2021 | Feb 14, 2022 | 11 | $175.9M | PMVPFHTXALEC | vs. Q3 2021 | SEC |
| Q3 2021 | Nov 15, 2021 | 10 | $205.7M | PMVPALECRAPT | vs. Q2 2021 | SEC |
| Q2 2021 | Nov 15, 2021Amended | 14 | $308.1M | PMVPNGMDNLI | vs. Q1 2021 | SEC |
| Q1 2021 | May 17, 2021 | 13 | $298.9M | PMVPNGMORIC | – | SEC |
13D and 13G filings
Companies where Euclidean Capital LLC reports owning 5% or more on Schedule 13D or 13G, and its latest filings.
Current stakes of 5% or more
Euclidean Capital LLC does not currently report owning 5% or more of any company.
Latest filings
5 filings on file made by Euclidean Capital LLC or listing it as a reporting person, newest first.
| Company | Filed (ET) | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| PMVPPMV Pharmaceuticals, Inc. | May 15, 20264:05 PM ET | 13G/A | 4.90%2.63M shares | –Below 5% | Mar 31, 2026 | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Feb 14, 2022 | 13G/AOld format | – | – | – | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Oct 18, 2021 | 13G/AOld format | – | – | – | SEC |
| PMVPPMV Pharmaceuticals, Inc. | May 7, 2021 | 13G/AOld format | – | – | – | SEC |
| PMVPPMV Pharmaceuticals, Inc. | Feb 12, 2021 | 13GOld format | – | New | – | SEC |